Hudson Executive Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Hudson Executive Capital’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-661,897	Closed	-$39.8M	–	9
2019 Q4	$39.8M	Sell	661,897 -148,468	-18%	-$8.85M	3.54%	5
2019 Q3	$45.8M	Sell	810,365 -1,412	-0.2%	-$79.4K	3.47%	7
2019 Q2	$45.2M	Sell	811,777 -159,223	-16%	-$8.3M	4.35%	5
2019 Q1	$49M	Hold	971,000	–	–	4.55%	4
2018 Q4	$39.1M	Hold	971,000	–	–	3.95%	5
2018 Q3	$67.3M	Hold	971,000	–	–	5.44%	5
2018 Q2	$73.5M	Hold	971,000	–	–	16.36%	2
2018 Q1	$51.2M	Hold	971,000	–	–	15.09%	2
2017 Q4	$51.9M	Hold	971,000	–	–	24.9%	1
2017 Q3	$57.9M	Buy	971,000 +20,400	+2%	+$1.23M	29.13%	1
2017 Q2	$75M	Hold	950,600	–	–	34.47%	1
2017 Q1	$78.8M	Hold	950,600	–	–	21.62%	1
2016 Q4	$75.4M	Hold	950,600	–	–	26.81%	1
2016 Q3	$66.5M	Hold	950,600	–	–	11.81%	2
2016 Q2	$36.9M	Buy	950,600 +528,600	+125%	+$22M	13.83%	4
2016 Q1	$17.1M	Buy	+422,000	New	+$26.8M	3.94%	10

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hudson Executive Capital's EGRX Position: Q1 2020 in Review

Hudson Executive Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2020, closing a stake of 661,897 shares — an estimated $39.8M sold.

Hudson Executive Capital first reported a position in EGRX in Q1 2016 and held it in 16 quarters. The position peaked at $78.8M in Q1 2017. 168 funds tracked by Wall St. Rank hold EGRX as of Q1 2020.

Hudson Executive Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Hudson Executive Capital sold 661,897 Eagle Pharmaceuticals, Inc. shares in Q1 2020, an estimated $39.8M.
Hudson Executive Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 16 quarters.
Hudson Executive Capital's Eagle Pharmaceuticals, Inc. position peaked at $78.8M in Q1 2017.
168 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2020.

Based on Hudson Executive Capital's 13F filing for Q1 2020, filed 15 May 2020.